UPDATE: Citi Lowers Baxter's PT

According to a research report published earlier today, Citi has lowered Baxter's

PT from $57 to $56. In the report, Citi said, “BAX's inability to provide more answers on HyQvia and the surprise $1B cost of a new plasma facility in GA offset a good underlying 1Q12 performance. With 1G supply constrained, it appears the swing factor in 2012 will be the ability to gain further U.S. market share in rFVIII.” Citi maintains its Neutral rating on Baxter International, which is currently trading at $54.23.